vTv Therapeutics Inc.
NASDAQ:VTVT
14.93 (USD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 2.018 | 4.005 | 6.414 | 2.764 | 12.434 | 0.291 | 0.634 | 0.519 | 1.549 | 0.976 |
| Cost of Revenue
| 0.09 | 0.092 | 0.089 | 11.015 | 15.119 | 23.035 | 39.64 | 45.748 | 29.584 | 18.729 | 25.434 |
| Gross Profit
| -0.09 | 1.926 | 3.916 | -4.601 | -12.355 | -10.601 | -39.349 | -45.114 | -29.065 | -17.18 | -24.458 |
| Gross Profit Ratio
| 0 | 0.954 | 0.978 | -0.717 | -4.47 | -0.853 | -135.22 | -71.158 | -56.002 | -11.091 | -25.059 |
| Reseach & Development Expenses
| 13.505 | 12.357 | 13.324 | 11.015 | 15.119 | 23.035 | 39.64 | 45.748 | 29.584 | 18.729 | 25.434 |
| General & Administrative Expenses
| 11.907 | 12.201 | 12.343 | 7.251 | 8.537 | 9.223 | 11.333 | 9.906 | 9.077 | 11.717 | 11.375 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 11.907 | 12.201 | 12.343 | 7.251 | 8.537 | 9.223 | 11.333 | 9.906 | 9.077 | 11.717 | 11.375 |
| Other Expenses
| 0 | -2.67 | 4.057 | -0.27 | 0.828 | -0.592 | -0.19 | -0.022 | -2.965 | -1.126 | -0.534 |
| Operating Expenses
| 25.412 | 24.558 | 25.667 | 18.266 | 23.656 | 32.258 | 50.973 | 55.654 | 38.661 | 30.446 | 36.809 |
| Operating Income
| -25.502 | -22.54 | -21.662 | -11.852 | -20.892 | -19.824 | -50.682 | -55.02 | -38.142 | -28.897 | -35.833 |
| Operating Income Ratio
| 0 | -11.169 | -5.409 | -1.848 | -7.559 | -1.594 | -174.165 | -86.782 | -73.491 | -18.655 | -36.714 |
| Total Other Income Expenses Net
| -0.464 | -2.333 | 4.046 | -0.95 | -0.946 | -0.592 | -0.19 | -0.022 | -2.965 | -1.195 | -0.548 |
| Income Before Tax
| -25.966 | -24.873 | -17.616 | -12.802 | -21.838 | -23.645 | -53.847 | -55.353 | -41.107 | -36.101 | -48.203 |
| Income Before Tax Ratio
| 0 | -12.326 | -4.399 | -1.996 | -7.901 | -1.902 | -185.041 | -87.308 | -79.204 | -23.306 | -49.388 |
| Income Tax Expense
| -5.716 | 0.2 | 0.115 | -3.975 | 0.1 | 0.2 | 0.8 | -39.001 | -14.11 | 4.883 | 11.288 |
| Net Income
| -20.25 | -25.073 | -17.731 | -8.827 | -21.938 | -7.911 | -16.144 | -16.352 | -27.498 | -36.101 | -48.203 |
| Net Income Ratio
| 0 | -12.425 | -4.427 | -1.376 | -7.937 | -0.636 | -55.478 | -25.792 | -52.983 | -23.306 | -49.388 |
| EPS
| -9.71 | -13.06 | -11.32 | -7.49 | -28.97 | -25.42 | -66.62 | -68.52 | -132.9 | -173.87 | -234.57 |
| EPS Diluted
| -9.71 | -13.06 | -11.32 | -7.49 | -28.97 | -25.42 | -66.62 | -68.52 | -132.9 | -173.87 | -234.57 |
| EBITDA
| -25.412 | -24.858 | -17.604 | -12.11 | -20.011 | -20.355 | -50.755 | -54.955 | -38.142 | -29.159 | -35.281 |
| EBITDA Ratio
| 0 | -12.318 | -4.396 | -1.888 | -7.24 | -1.637 | -174.416 | -86.68 | -73.491 | -18.824 | -36.149 |